Recombinant Anti-LYPD3 antibody [EPR9107] (ab151709)


  • Product name

    Anti-LYPD3 antibody [EPR9107]
    See all LYPD3 primary antibodies
  • Description

    Rabbit monoclonal [EPR9107] to LYPD3
  • Host species

  • Tested applications

    Suitable for: WB, IHC-P, IPmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide within Human LYPD3. The exact sequence is proprietary.

  • Positive control

    • BxPC3, HACAT cell lysates, Human skin tissue, Human esophagus lysates.
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.


  • Form

  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
  • Storage buffer

    Preservative: 0.01% Sodium azide
    Constituents: 40% Glycerol, 0.05% BSA, 59% PBS
  • Concentration information loading...
  • Purity

    Protein A purified
  • Clonality

  • Clone number

  • Isotype

  • Research areas


Our Abpromise guarantee covers the use of ab151709 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Predicted molecular weight: 36 kDa.
IHC-P 1/1000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

For unpurified use at 1/100 - 1/250.

IP 1/10 - 1/100.


  • Function

    Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression.
  • Tissue specificity

    Expressed in placenta, skin and urothelium. Found in suprabasal keratinocytes of chronic wounds. Weak expression is found in esophagus and peripheral blood mononuclear cells. Found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues, but not in adjacent normal tissues. High expression is found in the tumor component of some noninvasive superficial lesions and in invasive and metastatic urothelial cancers.
  • Sequence similarities

    Contains 2 UPAR/Ly6 domains.
  • Post-translational

    N-glycosylated and O-glycosylated.
  • Cellular localization

    Cell membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • 2310061G07Rik antibody
    • C4.4A antibody
    • GPI-anchored metastasis-associated protein C4.4A homolog antibody
    • GPI-anchored metastasis-associated protein homolog antibody
    • Ly6/PLAUR domain-containing protein 3 antibody
    • Lypd3 antibody
    • LYPD3_HUMAN antibody
    • Matrigel-induced gene C4 protein antibody
    • MIG-C4 antibody
    • SHINC3 antibody
    see all


  • All lanes : Anti-LYPD3 antibody [EPR9107] (ab151709) at 1/1000 dilution (purified)

    Lane 1 : HaCaT (Human skin keratinocyte) whole cell lysates
    Lane 2 : BxPC-3 (Human pancreas adenocarcinoma epithelial cell) whole cell lysates
    Lane 3 : Human esophagus lysates

    Lysates/proteins at 20 µg per lane.

    All lanes : Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/5000 dilution

    Predicted band size: 36 kDa

    Blocking and diluting buffer: 5% NFDM/TBST

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human skin tissue sections labeling LYPD3 with Purified ab151709 at 1:1000 dilution (1.01 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). Tissue was counterstained with Hematoxylin. ImmunoHistoProbe one step HRP Polymer (ready to use) secondary antibody was used at 1:0 dilution. PBS instead of the primary antibody was used as the negative control.

  • ab151709 (purified) at 1:50 dilution (2ug) immunoprecipitating LYPD3 in HaCaT (Human skin keratinocyte) whole cell lysate.
    Lane 1 (input): HaCaT (Human skin keratinocyte) whole cell lysate 10ug
    Lane 2 (+): ab151709 & HaCaT (Human skin keratinocyte) whole cell lysate
    Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab151709 in HaCaT (Human skin keratinocyte) whole cell lysate
    For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366) was used for detection at 1:1000 dilution.
    Blocking and diluting buffer: 5% NFDM/TBST.

  • All lanes : Anti-LYPD3 antibody [EPR9107] (ab151709) at 1/1000 dilution (unpurified)

    Lane 1 : BxPC3 cell lysate
    Lane 2 : HACAT cell lysate

    Lysates/proteins at 10 µg per lane.

    All lanes : Goat anti-rabbit HRP at 1/2000 dilution

    Predicted band size: 36 kDa

  • Immunohistochemical analysis of paraffin-embedded Human skin tissue labeling LYPD3 with unpurified ab151709 at 1/100 dilution.


This product has been referenced in:

  • Chen L  et al. TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma. J Cell Mol Med 22:1337-1349 (2018). Read more (PubMed: 29193723) »
See 1 Publication for this product

Customer reviews and Q&As


I have been informed by the lab that the immunogen used for creation of ab151709 is not N terminal but is instead located internally nearer the C terminus. The second rabbit monoclonal Ab155080 has been created from an immunogen corresponding to an area near the N terminus.

Read More

For licensing inquiries, please contact

Sign up